iBio raises $26M in PIPE led by Frazier Life Sciences to fund cardiometabolic programs

iBio, Inc.

Gross proceeds of ~$26M from sale of 11.06M shares/pre-funded warrants at $2.35/share.
Expected close on Jan 13, 2026; led by Frazier Life Sciences with other existing investors.
Proceeds to advance IBIO-610, IBIO-600, and myostatin/activin A bispecific programs.
Company expects cash runway extended into calendar 2028.
Leerink Partners lead placement agent; LifeSci Capital and Oppenheimer co-agents.

Key facts

Extracted from this filing and checked against the source text.

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.9

iBio, Inc. entered into Purchase Agreement with certain institutional investors valued at approximately $26 million (effective 2026-01-08).

Action: entry
Agreement: equity purchase
Counterparty: certain institutional investors
Value: approximately $26 million
Effective: 2026-01-08

Exact text from the filing

On January 8, 2026, iBio, Inc., a Delaware company (the “Company”), entered into a securities purchase agreement (the “Purchase Agreement”) with certain institutional investors (the “Investors”), pursuant to which the Company agreed to issue and sell to the Investors, in a private placement priced at-the-market consistent with the rules of the Nasdaq Stock Market LLC (the “Private Placement”) an aggregate of 1,408,481 shares (the “Shares”) of the Company’s common stock

View on SEC.gov

294 material agreements filed in the last 30 days. Browse all material agreements →

iBio, Inc. filing history →

Source: SEC EDGAR

accession 0001104659-26-002940

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.